0
Abstract: Poster Presentations |

COMPARATIVE STUDY ON EFFICACY OF INHALED PROCATEROL AND INHALED SALBUTAMOL DELIVERED BY METERED-DOSE INHALER ATTACHED TO A SPACER DEVICE IN MILD AND MODERATE ASTHMA EXACERBATION AMONG 6 TO 18 YEAR-OLDS FREE TO VIEW

Olivia Cristina Y. Go, MD*; Arnel Gerald Q. Jiao, MD; Gilda S. Erquiza, MD; Marilyn A. Argana, MD
Author and Funding Information

Philippine Children's Medical Center, Quezon City, Philippines


Chest


Chest. 2008;134(4_MeetingAbstracts):p51002. doi:10.1378/chest.134.4_MeetingAbstracts.p51002
Text Size: A A A
Published online

Abstract

PURPOSE: This study was undertaken to compare the efficacy of inhaled salbutamol and inhaled procaterol in the management of mild and moderate asthma exacerbation.

METHODS: This is a parallel, single blind randomized controlled clinical trial conducted to 32 children. Treatment was allocated randomly. Group 1 received 2 puffs of salbutamol (200 ug) while group 2 received 1 puff of procaterol (10 ug). These were administered every 20 minutes for 3 doses. Peak expiratory flow rate (PEFR), Modified Wood Downes’ (MWD) Clinical Asthma Score, heart rate and cardiac rate were reassessed at 20, 40, 60, 90, 120, 180, 240 and 300 minutes. Mean percent predicted PEFR and mean percent change in PEFR from baseline were computed. Outcome of each patient either discharged or requiring further treatment and adverse effects were determined.

RESULTS: The mean percent predicted PEFR and mean percent change in PEFR significantly increased in both groups (p<0.0001) over time. There was no significant difference between the 2 groups in mean percent predicted PEFR and mean percent change in PEFR at 0 to 240 minutes (p>0.05). At 300 minutes, these parameters decreased in group 1 while that in group 2 continued to increase. The MWD Asthma Scores in group 2 decreased at 240 and 300 minutes (p=0.032 and p=0.017, respectively) signifying improvement. Six patients (37.5%) required further treatment in the salbutamol group while 2 patients (12.5%) needed additional therapy in the procaterol group. However, this difference was not statistically significant. Adverse effects were not observed in both groups.

CONCLUSION: This study showed that inhaled salbutamol and inhaled procaterol were both efficacious in the management of mild to moderate exacerbation. A sustained and prolonged bronchodilator response was noted using procaterol.

CLINICAL IMPLICATIONS: The initial management of mild to moderate asthma exacerbation includes administration of inhaled short-acting bronchodilator(SABA). At present, the long-acting bronchodilator (LABA) is recommended for use as “symptom controller“. This study showed that inhaled procaterol, a LABA, is as efficacious as salbutamol, a SABA, and has a sustained bronchodilatory action.

DISCLOSURE: Olivia Cristina Go, No Financial Disclosure Information; No Product/Research Disclosure Information

Tuesday, October 28, 2008

1:00 PM - 2:15 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543